HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $31 Price Target

HC Wainwright & Co. analyst Matthew Keller has reiterated a Buy rating on Acurx Pharmaceuticals (NASDAQ: ACXP) and maintained a price target of $31 for the stock.